Agathoklis Efthymiadis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Agathoklis Efthymiadis has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Anastasios Bastounis
Sheffield Centre for Health and Related Research (SCHARR), Division of Population Health, School of Medicine and Population Health, University of Sheffield, Sheffield, UK
3 shared publicationsKonstantinos Tsikopoulos
Orthopaedic Department, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK
3 shared publicationsMarianthi Bourlaki
Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3 shared publications- Aparna Pal
Oxford Centre for Diabetes, Endocrinology & Metabolism Churchill Hospital Oxford UK
2 shared publications Dimitrios Spinos
Department of Otorhinolaryngology, Head and Neck Surgery, South Warwickshire University Hospitals NHS Trust, Warwick, UK
2 shared publications- Alexander N. Comninos
Imperial College London
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by Springer Nature
Investigating how a natural hormone called kisspeptin affects social and emotional brain processing
- 31 March 2026
- Published by Springer Nature
Open AccessInvestigating how a natural hormone called kisspeptin affects social and emotional brain processing
- 5 September 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 2251-2261
The impact of closed-loop automated insulin delivery systems on hypoglycaemia awareness in people living with type 1 diabetes: A systematic review and meta-analysis
Objectives Impaired awareness of hyperglycaemia (IAH) affects approximately 20–40% of people living with type 1 diabetes (T1D), predisposing them to severe hypoglycaemia. This systematic review evaluated the efficacy of closed-loop automated insulin delivery systems (CL-AID) in restoring IAH compared with standard diabetes care, including other diabetes technologies. Methods Six electronic databases were searched for published and unpublished observational and randomised-control studies (RCTs) from inception to 29th of May 2024. The results of observational studies and RCTs were meta-analysed separately to calculate the effect of CL-AID on IAH in people living with T1D. Quality assessment of studies was performed using the Joanna-Briggs appraisal tool for cohort studies and the Risk of Bias (Rob-2) tool for RCTs. Results Meta-analysis of four prospective observations studies (n = 583) demonstrated a statistically significant improvement in hypoglycaemia awareness upon transition to a hybrid closed-loop (HCL) system compared with standard diabetes care in people with T1D, Clarke score mean difference (MD) of -0.45 (-0.69 to -0.22, p = 0.0001). However, this was less than 1 point, which is the minimum clinically important difference (MCID) of Clarke score. Meta-analysis of three RCTs (n = 55) comparing standard diabetes care did not demonstrate any statistically significant effect on hypoglycaemia awareness, Clarke score MD of -0.69 (-1.89 to 0.50, p = 0.26). Conclusions This systematic review demonstrated that transition from standard diabetes care to HCL has the potential to improve hypoglycaemia awareness in people with T1D and IAH, but this might not be of major clinical significance. Hence, psychoeducational interventions continue to be the cornerstone of IAH management. Novel therapeutic modalities, such as bi-hormonal automated delivery systems, need to be further explored to help restore hypoglycaemia awareness.
- 5 September 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (2) , 2251-2261
The impact of closed-loop automated insulin delivery systems on hypoglycaemia awareness in people living with type 1 diabetes: A systematic review and meta-analysis
Objectives Impaired awareness of hyperglycaemia (IAH) affects approximately 20–40% of people living with type 1 diabetes (T1D), predisposing them to severe hypoglycaemia. This systematic review evaluated the efficacy of closed-loop automated insulin delivery systems (CL-AID) in restoring IAH compared with standard diabetes care, including other diabetes technologies. Methods Six electronic databases were searched for published and unpublished observational and randomised-control studies (RCTs) from inception to 29th of May 2024. The results of observational studies and RCTs were meta-analysed separately to calculate the effect of CL-AID on IAH in people living with T1D. Quality assessment of studies was performed using the Joanna-Briggs appraisal tool for cohort studies and the Risk of Bias (Rob-2) tool for RCTs. Results Meta-analysis of four prospective observations studies (n = 583) demonstrated a statistically significant improvement in hypoglycaemia awareness upon transition to a hybrid closed-loop (HCL) system compared with standard diabetes care in people with T1D, Clarke score mean difference (MD) of -0.45 (-0.69 to -0.22, p = 0.0001). However, this was less than 1 point, which is the minimum clinically important difference (MCID) of Clarke score. Meta-analysis of three RCTs (n = 55) comparing standard diabetes care did not demonstrate any statistically significant effect on hypoglycaemia awareness, Clarke score MD of -0.69 (-1.89 to 0.50, p = 0.26). Conclusions This systematic review demonstrated that transition from standard diabetes care to HCL has the potential to improve hypoglycaemia awareness in people with T1D and IAH, but this might not be of major clinical significance. Hence, psychoeducational interventions continue to be the cornerstone of IAH management. Novel therapeutic modalities, such as bi-hormonal automated delivery systems, need to be further explored to help restore hypoglycaemia awareness.
- Open Access
- 17 January 2024
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 7 (1) , e467
Copeptin and the syndrome of inappropriate antidiuresis (SIAD) after pituitary transsphenoidal surgery
Objective: This study evaluates the predictive value of copeptin for syndrome of inappropriate antidiuresis (SIAD) postpituitary transsphenoidal surgery (TSS).Design: Data from 133 consecutive patients undergoing TSS (November 2017–October 2022) at Oxford University Hospitals NHS trust are presented in this retrospective study.Methods: Logistic regression (LR) and receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic utility of copeptin. The Mann–Whitney U test was used to compare copeptin levels between the SIAD and no SIAD groups.Results: Fourteen patients (10.8%) developed SIAD. Copeptin was available in 121, 53 and 87 patients for Days 1, 241 and 8 post‐TSS, respectively. LR for Day 1 copeptin to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 42 0.84–1.20, p = .99), area under‐ROC curve (AUC) was 0.49; Day 2 copeptin OR was 0.65 (95%CI 0.39–1.19, 43 p = .77), AUC was 0.57 LR for Day 1 sodium to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 0.85–1.21, p = .99), AUC was 0.50.Conclusions: In conclusion, our data provide no evidence for copeptin as a predictive marker for post‐TSS SIAD.
- 17 January 2024
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 7 (1) , e467
Open AccessCopeptin and the syndrome of inappropriate antidiuresis (SIAD) after pituitary transsphenoidal surgery
Objective: This study evaluates the predictive value of copeptin for syndrome of inappropriate antidiuresis (SIAD) postpituitary transsphenoidal surgery (TSS).Design: Data from 133 consecutive patients undergoing TSS (November 2017–October 2022) at Oxford University Hospitals NHS trust are presented in this retrospective study.Methods: Logistic regression (LR) and receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic utility of copeptin. The Mann–Whitney U test was used to compare copeptin levels between the SIAD and no SIAD groups.Results: Fourteen patients (10.8%) developed SIAD. Copeptin was available in 121, 53 and 87 patients for Days 1, 241 and 8 post‐TSS, respectively. LR for Day 1 copeptin to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 42 0.84–1.20, p = .99), area under‐ROC curve (AUC) was 0.49; Day 2 copeptin OR was 0.65 (95%CI 0.39–1.19, 43 p = .77), AUC was 0.57 LR for Day 1 sodium to predict SIAD gave an odds ratio (OR) of 1.0 (95%CI 0.85–1.21, p = .99), AUC was 0.50.Conclusions: In conclusion, our data provide no evidence for copeptin as a predictive marker for post‐TSS SIAD.
- 30 November 2023
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (5) , 488-501
Adequacy of thyroid hormone replacement for people with hypothyroidism in real‐world settings: A systematic review and meta‐analysis of observational studies
Objective: Thyroid hormone under‐replacement and over‐replacement are associated with adverse health outcomes. This systematic review aimed to evaluate the extent of thyroid hormone replacement adequacy for patients with known hypothyroidism in real‐word settings, excluding those receiving thyroid hormone suppressive therapy as thyroid cancer treatment.Design: Four electronic databases (Embase [Ovid], Medline [Ovid], PubMed and SCOPUS) were searched for published and unpublished observational studies until 12 December 2022. The results of the studies were meta‐analysed to calculate pooled prevalence estimates for thyroid hormone supplementation adequacy, over‐replacement and under‐replacement. Quality assessment of studies was performed using the Joanna‐Briggs appraisal tool for prevalence studies.Results: Seven studies with a total of 4230 patients were eligible for quantitative synthesis. The pooled prevalence estimates of adequate thyroid replacement, over‐replacement and under‐replacement were 0.55 (95% confidence interval [CI]: 0.49–0.60, p = .001), 0.20 (95% CI: 0.14–0.27, p = .001) and 0.24 (95% CI: 0.13–0.36, p = .001), respectively. Four studies subclassified hypothyroidism and hyperthyroidism into overt and subclinical. The pooled prevalence of overt and subclinical hyperthyroidism was 0.04 (95% CI: 0.00–0.11, p = .01) and 0.17 (95% CI: 0.09–0.27 p = .001), respectively. For overt and subclinical hypothyroidism, the pooled prevalence was 0.02 (95% CI: 0.01–0.03, p = .001) and 0.20 (95% CI: 0.12–0.29, p = .001), respectively.Conclusions: On average, approximately half of patients with hypothyroidism are only treated to target euthyroidism. In real‐world practice, a significant number of patients are over‐treated or under‐treated, leading to adverse healthcare outcomes. It is imperative that more effective thyroid monitoring strategies be implemented, with an emphasis on primary care thyroid function monitoring, to minimise inappropriate thyroid replacement treatments and optimise healthcare outcomes at a population level.
- 30 November 2023
- Published by Wiley in Clinical Endocrinology
- Vol. 100 (5) , 488-501
Adequacy of thyroid hormone replacement for people with hypothyroidism in real‐world settings: A systematic review and meta‐analysis of observational studies
Objective: Thyroid hormone under‐replacement and over‐replacement are associated with adverse health outcomes. This systematic review aimed to evaluate the extent of thyroid hormone replacement adequacy for patients with known hypothyroidism in real‐word settings, excluding those receiving thyroid hormone suppressive therapy as thyroid cancer treatment.Design: Four electronic databases (Embase [Ovid], Medline [Ovid], PubMed and SCOPUS) were searched for published and unpublished observational studies until 12 December 2022. The results of the studies were meta‐analysed to calculate pooled prevalence estimates for thyroid hormone supplementation adequacy, over‐replacement and under‐replacement. Quality assessment of studies was performed using the Joanna‐Briggs appraisal tool for prevalence studies.Results: Seven studies with a total of 4230 patients were eligible for quantitative synthesis. The pooled prevalence estimates of adequate thyroid replacement, over‐replacement and under‐replacement were 0.55 (95% confidence interval [CI]: 0.49–0.60, p = .001), 0.20 (95% CI: 0.14–0.27, p = .001) and 0.24 (95% CI: 0.13–0.36, p = .001), respectively. Four studies subclassified hypothyroidism and hyperthyroidism into overt and subclinical. The pooled prevalence of overt and subclinical hyperthyroidism was 0.04 (95% CI: 0.00–0.11, p = .01) and 0.17 (95% CI: 0.09–0.27 p = .001), respectively. For overt and subclinical hypothyroidism, the pooled prevalence was 0.02 (95% CI: 0.01–0.03, p = .001) and 0.20 (95% CI: 0.12–0.29, p = .001), respectively.Conclusions: On average, approximately half of patients with hypothyroidism are only treated to target euthyroidism. In real‐world practice, a significant number of patients are over‐treated or under‐treated, leading to adverse healthcare outcomes. It is imperative that more effective thyroid monitoring strategies be implemented, with an emphasis on primary care thyroid function monitoring, to minimise inappropriate thyroid replacement treatments and optimise healthcare outcomes at a population level.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Coexistence of cranial diabetes insipidous and heart failure with reduced ejection fraction: a case report presenting challenges and unique therapeutic opportunities
History: We present the case of a 47-year-old man with heart failure (HF) and cranial diabetes insipidus (CDI) secondary to Langerhans-cell-histiocytosis. In the context of worsening HF with increasing shortness of breath and fluid retention, careful desmopressin dose reduction provided adequate aquaresis to restore euvolemia, obviating the need for usual diuretic treatments. Investigations: Echocardiography and a cardiac MRI revealed a non-dilated but severely impaired left ventricle (ejection-fraction 35%). His right ventricle was impaired but non- dilated. Sodium, paired osmolarities were within reference range throughout follow-up. Treatment: Careful reduction of desmopressin from maintenance dose of 200 mg thrice-daily to 200 mg twice-daily allowed for adequate aquaresis and resolution of worsening HF symptoms. Iatrogenic diuresis was not indicated. Desmopressin adjustment manoeuvres were adequate to restore euvolemia, with urine output averaging 2-2.5 litres. After resolution of HF symptoms, desmopressin was switched back to 200 mg thrice-daily. Maximum tolerated Losartan dose was 50 mg. Beta-blockade, mineralocorticoid-receptor or angiotensin-receptor- neprilysin inhibition were not tolerated. SGLT-2 inhibition has not been trialled yet. Conclusions: The co-existence of CDI and HF presents both challenges and unique therapeutic opportunities. Desmopressin dose manoeuvres produced adequate aquaresis, leading to restoration of euvolemia and rapid symptomatic relief. Dizziness, polyuria, thirst limited tolerability of HF prognostication drugs. Close endocrinology and cardiology co-operation was key in avoiding admissions with decompensated HF. This case provides insights for novel drug development targets. Our patient has complete absence of V1a-receptor activity (absent endogenous vasopressin). V2-receptor activity is dose-dependent based on desmopressin manipulation. Inducing a similarly balanced V1a/V2-receptor activity state pharmacologically could translate to clinically meaningful aquaresis, obviating V1a-receptor induced deleterious vasoconstriction and cardiac remodelling. This could represent a novel HF treatment target, potentially more effective than selective V2- receptor antagonism (tolvaptan) associated with toxic V1a-receptor activation via rebound endogenous vasopressin release. Pecavaptan, a novel balanced oral V1a/V2-receptor antagonist is under development.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Coexistence of cranial diabetes insipidous and heart failure with reduced ejection fraction: a case report presenting challenges and unique therapeutic opportunities
History: We present the case of a 47-year-old man with heart failure (HF) and cranial diabetes insipidus (CDI) secondary to Langerhans-cell-histiocytosis. In the context of worsening HF with increasing shortness of breath and fluid retention, careful desmopressin dose reduction provided adequate aquaresis to restore euvolemia, obviating the need for usual diuretic treatments. Investigations: Echocardiography and a cardiac MRI revealed a non-dilated but severely impaired left ventricle (ejection-fraction 35%). His right ventricle was impaired but non- dilated. Sodium, paired osmolarities were within reference range throughout follow-up. Treatment: Careful reduction of desmopressin from maintenance dose of 200 mg thrice-daily to 200 mg twice-daily allowed for adequate aquaresis and resolution of worsening HF symptoms. Iatrogenic diuresis was not indicated. Desmopressin adjustment manoeuvres were adequate to restore euvolemia, with urine output averaging 2-2.5 litres. After resolution of HF symptoms, desmopressin was switched back to 200 mg thrice-daily. Maximum tolerated Losartan dose was 50 mg. Beta-blockade, mineralocorticoid-receptor or angiotensin-receptor- neprilysin inhibition were not tolerated. SGLT-2 inhibition has not been trialled yet. Conclusions: The co-existence of CDI and HF presents both challenges and unique therapeutic opportunities. Desmopressin dose manoeuvres produced adequate aquaresis, leading to restoration of euvolemia and rapid symptomatic relief. Dizziness, polyuria, thirst limited tolerability of HF prognostication drugs. Close endocrinology and cardiology co-operation was key in avoiding admissions with decompensated HF. This case provides insights for novel drug development targets. Our patient has complete absence of V1a-receptor activity (absent endogenous vasopressin). V2-receptor activity is dose-dependent based on desmopressin manipulation. Inducing a similarly balanced V1a/V2-receptor activity state pharmacologically could translate to clinically meaningful aquaresis, obviating V1a-receptor induced deleterious vasoconstriction and cardiac remodelling. This could represent a novel HF treatment target, potentially more effective than selective V2- receptor antagonism (tolvaptan) associated with toxic V1a-receptor activation via rebound endogenous vasopressin release. Pecavaptan, a novel balanced oral V1a/V2-receptor antagonist is under development.
- Open Access
- 1 June 2022
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2022 (1)
A case of ChAdOx1 vaccine-induced thrombocytopenia and thrombosis syndrome leading to bilateral adrenal haemorrhage and adrenal insufficiency
Summary Vaccine-induced thrombosis and thrombocytopenia (VITT) after vaccination against SARS-CoV-2 with the adenoviral vector-based vaccines ChAdOx1 and Ad26.COV2.S has been associated with adrenal pathology, such as bilateral adrenal vein thrombosis, adrenal cortex haemorrhage and adrenal insufficiency in 6% of patients. We report the case of a 23-year-old woman who presented at 8 days after ChAdOx1 vaccination with a low platelet count of 43 × 109/L, raised d dimers >100 000 ng/mL and multiple lobar and segmental pulmonary emboli. Anti-platelet factor 4 antibodies were detected confirming definite VITT in accordance with the UK diagneostic criteria. At 16 days post-vaccine, further imaging showed bilateral adrenal haemorrhage, non-occlusive splenic vein thrombosis and right ventricular thrombosis. Her cortisol level was 9/L, raised d dimers >100 000 ng/mL and multiple lobar and segmental pulmonary emboli. Anti-platelet factor 4 antibodies were detected confirming definite VITT in accordance with the UK diagneostic criteria. At 16 days post-vaccine, further imaging showed bilateral adrenal haemorrhage, non-occlusive splenic vein thrombosis and right ventricular thrombosis. Her cortisol level was <25 nmol/L. She was treated with anticoagulation, plasmapheresis, immunosuppression and steroid replacement. She had high anti-spike titre and positive anti-nucleocapsid titres for SARS-CoV-2. She developed seizures secondary to posterior reversible encephalopathy, requiring intensive care. After 4 weeks in hospital, she was discharged on warfarin, hydrocortisone and fludrocortisone replacement. Short synacthen tests 3 and 9 months later showed no recovery of adrenal function, although magnetic resonance imaging of the adrenal glands showed resolving adrenal haemorrhage. Adrenal insufficiency secondary to bilateral adrenal vein thrombosis and adrenal haemorrhage should be suspected in patients with VITT and treated promptly. Adrenal vein thrombosis can occur either as the initial presentation of VITT or days to weeks after the development of thrombosis in other sites. Further studies are required to provide insight on adrenal function recovery after VITT. Learning points Adrenal insufficiency secondary to bilateral adrenal vein thrombosis and adrenal cortex haemorrhage should be suspected in patients with vaccine-induced thrombosis and thrombocytopenia (VITT) and treated promptly. Adrenal vein thrombosis can occur as the initial presentation of VITT or even days to weeks later after the development of thrombosis in other more classic sites (e.g. pulmonary or cerebral vasculature). Completion of vaccination schedule against SARS-CoV-2 post-VITT using an mRNA-based vaccine should be recommended to patients post-VITT as mRNA-based vaccines have not been associated with VITT but confer protection against SARS-CoV-2. There is paucity of data regarding the potential for recovery of adrenal function after bilateral adrenal haemorrhage in the context of VITT, and thus, more studies are needed to inform clinical practice. The need for disease registries for rare conditions, such as VITT, is crucial as direct cooperation and sharing of information by clinicians might enable quicker identification of disease patterns than would have been possible via established reporting tools of adverse events.
- 1 June 2022
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2022 (1)
Open AccessA case of ChAdOx1 vaccine-induced thrombocytopenia and thrombosis syndrome leading to bilateral adrenal haemorrhage and adrenal insufficiency
Summary Vaccine-induced thrombosis and thrombocytopenia (VITT) after vaccination against SARS-CoV-2 with the adenoviral vector-based vaccines ChAdOx1 and Ad26.COV2.S has been associated with adrenal pathology, such as bilateral adrenal vein thrombosis, adrenal cortex haemorrhage and adrenal insufficiency in 6% of patients. We report the case of a 23-year-old woman who presented at 8 days after ChAdOx1 vaccination with a low platelet count of 43 × 109/L, raised d dimers >100 000 ng/mL and multiple lobar and segmental pulmonary emboli. Anti-platelet factor 4 antibodies were detected confirming definite VITT in accordance with the UK diagneostic criteria. At 16 days post-vaccine, further imaging showed bilateral adrenal haemorrhage, non-occlusive splenic vein thrombosis and right ventricular thrombosis. Her cortisol level was 9/L, raised d dimers >100 000 ng/mL and multiple lobar and segmental pulmonary emboli. Anti-platelet factor 4 antibodies were detected confirming definite VITT in accordance with the UK diagneostic criteria. At 16 days post-vaccine, further imaging showed bilateral adrenal haemorrhage, non-occlusive splenic vein thrombosis and right ventricular thrombosis. Her cortisol level was <25 nmol/L. She was treated with anticoagulation, plasmapheresis, immunosuppression and steroid replacement. She had high anti-spike titre and positive anti-nucleocapsid titres for SARS-CoV-2. She developed seizures secondary to posterior reversible encephalopathy, requiring intensive care. After 4 weeks in hospital, she was discharged on warfarin, hydrocortisone and fludrocortisone replacement. Short synacthen tests 3 and 9 months later showed no recovery of adrenal function, although magnetic resonance imaging of the adrenal glands showed resolving adrenal haemorrhage. Adrenal insufficiency secondary to bilateral adrenal vein thrombosis and adrenal haemorrhage should be suspected in patients with VITT and treated promptly. Adrenal vein thrombosis can occur either as the initial presentation of VITT or days to weeks after the development of thrombosis in other sites. Further studies are required to provide insight on adrenal function recovery after VITT. Learning points Adrenal insufficiency secondary to bilateral adrenal vein thrombosis and adrenal cortex haemorrhage should be suspected in patients with vaccine-induced thrombosis and thrombocytopenia (VITT) and treated promptly. Adrenal vein thrombosis can occur as the initial presentation of VITT or even days to weeks later after the development of thrombosis in other more classic sites (e.g. pulmonary or cerebral vasculature). Completion of vaccination schedule against SARS-CoV-2 post-VITT using an mRNA-based vaccine should be recommended to patients post-VITT as mRNA-based vaccines have not been associated with VITT but confer protection against SARS-CoV-2. There is paucity of data regarding the potential for recovery of adrenal function after bilateral adrenal haemorrhage in the context of VITT, and thus, more studies are needed to inform clinical practice. The need for disease registries for rare conditions, such as VITT, is crucial as direct cooperation and sharing of information by clinicians might enable quicker identification of disease patterns than would have been possible via established reporting tools of adverse events.
- 1 March 2022
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 27 (2) , 456-462
Which is the optimal minimally invasive treatment for osteoid osteoma of the hip? A systematic review and proportional meta-analysis
- 1 March 2022
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 27 (2) , 456-462
Which is the optimal minimally invasive treatment for osteoid osteoma of the hip? A systematic review and proportional meta-analysis
- 28 January 2022
- Published by Springer Nature in Diabetology International
- Vol. 13 (3) , 513-521
The effectiveness of psychological interventions on mental health and quality of life in people living with type 1 diabetes: a systematic review and meta-analysis
Background Living with type 1 diabetes can be associated with significant psychological morbidity, poor glycaemic control, and increased risk for microvascular complications. This systematic review sought to investigate the effects of psychological interventions on depression, anxiety, diabetes-related distress, quality of life, and glycaemic control in people with type 1 diabetes. Methods Eight electronic databases were searched for published and unpublished randomised controlled trials. Screening, data extraction, and risk of bias assessment (using the Cochrane Collaboration tool for assessing risk of bias 2.0) were independently undertaken by two study authors. The results of the studies were meta-analysed, implementing a random-effects model. The Grading of Recommendations Assessment and Development and Evaluation (GRADE) system was used to determine the confidence in the effect estimates. Results Twenty studies were identified. Non-significant standardised mean differences (SMD) were found for depression symptoms (SMD = − 0.17, 95% CI [− 0.41, 0.07], p = 0.16) and diabetes-related distress (SMD = − 0.12, 95% CI [− 0.27, 0.04], p = 0.13). Significant SMD was found for quality of life (SMD = 0.27, 95% CI [0.11, 0.42], p = 0.0007). Significant mean difference (MD) was found for HbA1c (MD = − 0.26, 95% CI [− 0.51, − 0.01], p = 0.04). Prespecified subgroup analysis for cognitive behaviour-based interventions showed significant improvement for HbA1c (MD = − 0.23, 95% CI [− 0.44, − 0.02], p = 0.03). Conclusions Psychological interventions were found to significantly increase quality of life and promote glucose control in people with type 1 diabetes. Depending on their cost-effectiveness, psychological interventions could be incorporated in routine clinical practice for people with type 1 diabetes and concomitant psychological morbidity.
- 28 January 2022
- Published by Springer Nature in Diabetology International
- Vol. 13 (3) , 513-521
The effectiveness of psychological interventions on mental health and quality of life in people living with type 1 diabetes: a systematic review and meta-analysis
Background Living with type 1 diabetes can be associated with significant psychological morbidity, poor glycaemic control, and increased risk for microvascular complications. This systematic review sought to investigate the effects of psychological interventions on depression, anxiety, diabetes-related distress, quality of life, and glycaemic control in people with type 1 diabetes. Methods Eight electronic databases were searched for published and unpublished randomised controlled trials. Screening, data extraction, and risk of bias assessment (using the Cochrane Collaboration tool for assessing risk of bias 2.0) were independently undertaken by two study authors. The results of the studies were meta-analysed, implementing a random-effects model. The Grading of Recommendations Assessment and Development and Evaluation (GRADE) system was used to determine the confidence in the effect estimates. Results Twenty studies were identified. Non-significant standardised mean differences (SMD) were found for depression symptoms (SMD = − 0.17, 95% CI [− 0.41, 0.07], p = 0.16) and diabetes-related distress (SMD = − 0.12, 95% CI [− 0.27, 0.04], p = 0.13). Significant SMD was found for quality of life (SMD = 0.27, 95% CI [0.11, 0.42], p = 0.0007). Significant mean difference (MD) was found for HbA1c (MD = − 0.26, 95% CI [− 0.51, − 0.01], p = 0.04). Prespecified subgroup analysis for cognitive behaviour-based interventions showed significant improvement for HbA1c (MD = − 0.23, 95% CI [− 0.44, − 0.02], p = 0.03). Conclusions Psychological interventions were found to significantly increase quality of life and promote glucose control in people with type 1 diabetes. Depending on their cost-effectiveness, psychological interventions could be incorporated in routine clinical practice for people with type 1 diabetes and concomitant psychological morbidity.
- Open Access
- 1 March 2020
- Published by Elsevier in Clinical Medicine
- Vol. 20 (2) , s20
Anti-HER2 therapy-associated cardiotoxicity in breast cancer patients: analysis of real-world data from a UK cancer centre
Patients with breast cancer receiving anti-HER2 therapy between June 2018 and June 2019 at SLCC and ASPH were included in the analysis. Data on patient demographics, chemotherapy and anti-HER2 therapy details, and LVEF values were obtained from the systemic anti-cancer therapy electronic prescribing system and patient records.
- 1 March 2020
- Published by Elsevier in Clinical Medicine
- Vol. 20 (2) , s20
Open AccessAnti-HER2 therapy-associated cardiotoxicity in breast cancer patients: analysis of real-world data from a UK cancer centre
Patients with breast cancer receiving anti-HER2 therapy between June 2018 and June 2019 at SLCC and ASPH were included in the analysis. Data on patient demographics, chemotherapy and anti-HER2 therapy details, and LVEF values were obtained from the systemic anti-cancer therapy electronic prescribing system and patient records.